Dr Agnes Tallet speaks to ecancer about IORT use at the Institute Paoli-Calmettes in Marseilles, France. Patients eligible for IORT at this institute should be 50 years old with P1, N0, and non-globular grade 1 tumours without extensive DCIS and should be ER+ and HER2+.
Currently, INTRABEAM 50kv photon beam treatment in an isotopic shape is used at the Institute Paoli-Calmettes. Dr Tallet discusses how multidisciplinary teams collaborate for patient care and how treatment options are communicated to patients.
She concludes by emphasizing that patients eligible for IORT who are treated with IORT and endocrine therapy experience a recurrence rate of 1.5% which validates this treatment option for them.